Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey. more
Time Frame | IMNN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.75% | -1.8% | -0.77% |
1-Month Return | 1.39% | -3.48% | 0.71% |
3-Month Return | -23.96% | -7.2% | 8.81% |
6-Month Return | -34.36% | -1.54% | 12.32% |
1-Year Return | -3.43% | 8.39% | 30.57% |
3-Year Return | -91.11% | 6.07% | 29.21% |
5-Year Return | -96.27% | 44.07% | 91.95% |
10-Year Return | -99.83% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 500.00K | 500.00K | 500.00K | 500.00K | 125.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":25,"profit":true}] |
Cost of Revenue | 13.07M | 11.34M | 702.92K | 731.63K | 720.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":86.83,"profit":true},{"date":"2021-12-31","value":5.38,"profit":true},{"date":"2022-12-31","value":5.6,"profit":true},{"date":"2023-12-31","value":5.51,"profit":true}] |
Gross Profit | (12.57M) | (10.84M) | (202.92K) | (231.63K) | (720.00K) | [{"date":"2019-12-31","value":-1256530900,"profit":false},{"date":"2020-12-31","value":-1084481900,"profit":false},{"date":"2021-12-31","value":-20291800,"profit":false},{"date":"2022-12-31","value":-23162900,"profit":false},{"date":"2023-12-31","value":-72000500,"profit":false}] |
Gross Margin | (2513.06%) | (2168.96%) | (40.58%) | (46.33%) | (576.00%) | [{"date":"2019-12-31","value":-2513.06,"profit":false},{"date":"2020-12-31","value":-2168.96,"profit":false},{"date":"2021-12-31","value":-40.58,"profit":false},{"date":"2022-12-31","value":-46.33,"profit":false},{"date":"2023-12-31","value":-576,"profit":false}] |
Operating Expenses | 21.07M | 18.99M | 21.51M | 25.42M | 20.31M | [{"date":"2019-12-31","value":82.86,"profit":true},{"date":"2020-12-31","value":74.68,"profit":true},{"date":"2021-12-31","value":84.6,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":79.89,"profit":true}] |
Operating Income | (20.57M) | (18.49M) | (21.01M) | (24.92M) | (21.03M) | [{"date":"2019-12-31","value":-2056547300,"profit":false},{"date":"2020-12-31","value":-1848641200,"profit":false},{"date":"2021-12-31","value":-2100700000,"profit":false},{"date":"2022-12-31","value":-2492200000,"profit":false},{"date":"2023-12-31","value":-2103043000,"profit":false}] |
Total Non-Operating Income/Expense | 947.05K | (6.07M) | (1.70M) | (17.12M) | 1.09M | [{"date":"2019-12-31","value":87.25,"profit":true},{"date":"2020-12-31","value":-559.09,"profit":false},{"date":"2021-12-31","value":-156.36,"profit":false},{"date":"2022-12-31","value":-1576.89,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (18.67M) | (23.33M) | (22.15M) | (37.47M) | (20.80M) | [{"date":"2019-12-31","value":-1866800700,"profit":false},{"date":"2020-12-31","value":-2332938400,"profit":false},{"date":"2021-12-31","value":-2215300000,"profit":false},{"date":"2022-12-31","value":-3746500000,"profit":false},{"date":"2023-12-31","value":-2079536200,"profit":false}] |
Income Taxes | (1.82M) | (1.85M) | (1.38M) | (1.57M) | (1.28M) | [{"date":"2019-12-31","value":-181647400,"profit":false},{"date":"2020-12-31","value":-184582300,"profit":false},{"date":"2021-12-31","value":-138400000,"profit":false},{"date":"2022-12-31","value":-156700000,"profit":false},{"date":"2023-12-31","value":-128038500,"profit":false}] |
Income After Taxes | (16.85M) | (21.48M) | (20.77M) | (35.90M) | (19.51M) | [{"date":"2019-12-31","value":-1685153300,"profit":false},{"date":"2020-12-31","value":-2148356100,"profit":false},{"date":"2021-12-31","value":-2076900000,"profit":false},{"date":"2022-12-31","value":-3589800000,"profit":false},{"date":"2023-12-31","value":-1951497700,"profit":false}] |
Income From Continuous Operations | (16.85M) | (21.48M) | (20.77M) | (35.90M) | (27.86M) | [{"date":"2019-12-31","value":-1685153300,"profit":false},{"date":"2020-12-31","value":-2148356100,"profit":false},{"date":"2021-12-31","value":-2076925000,"profit":false},{"date":"2022-12-31","value":-3589800000,"profit":false},{"date":"2023-12-31","value":-2785951900,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (16.85M) | (21.48M) | (20.77M) | (35.90M) | (19.51M) | [{"date":"2019-12-31","value":-1685153300,"profit":false},{"date":"2020-12-31","value":-2148356100,"profit":false},{"date":"2021-12-31","value":-2076900000,"profit":false},{"date":"2022-12-31","value":-3589800000,"profit":false},{"date":"2023-12-31","value":-1951497700,"profit":false}] |
EPS (Diluted) | (11.10) | (10.05) | (6.77) | (5.17) | (2.18) | [{"date":"2019-12-31","value":-1110,"profit":false},{"date":"2020-12-31","value":-1005,"profit":false},{"date":"2021-12-31","value":-677,"profit":false},{"date":"2022-12-31","value":-517,"profit":false},{"date":"2023-12-31","value":-218,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IMNN | |
---|---|
Cash Ratio | 1.89 |
Current Ratio | 2.30 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IMNN | |
---|---|
ROA (LTM) | -67.08% |
ROE (LTM) | -148.12% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IMNN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.57 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IMNN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 17.94 |
P/B | 1.59 |
Price/FCF | NM |
EV/R | 4.00 |
EV/Ebitda | 0.91 |
Imunon Inc (IMNN) share price today is $0.8402
Yes, Indians can buy shares of Imunon Inc (IMNN) on Vested. To buy Imunon Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMNN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Imunon Inc (IMNN) via the Vested app. You can start investing in Imunon Inc (IMNN) with a minimum investment of $1.
You can invest in shares of Imunon Inc (IMNN) via Vested in three simple steps:
The 52-week high price of Imunon Inc (IMNN) is $3.65. The 52-week low price of Imunon Inc (IMNN) is $0.48.
The price-to-earnings (P/E) ratio of Imunon Inc (IMNN) is
The price-to-book (P/B) ratio of Imunon Inc (IMNN) is 1.59
The dividend yield of Imunon Inc (IMNN) is 0.00%
The market capitalization of Imunon Inc (IMNN) is $13.04M
The stock symbol (or ticker) of Imunon Inc is IMNN